Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)
Vir Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $15
Vir Biotechnology Analyst Ratings
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $13 to $28
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)
Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Vir Biotechnology (VIR)
Strategic Restructuring and Portfolio Diversification Solidify Buy Rating for Vir Biotechnology
Barclays Reaffirms Their Buy Rating on Vir Biotechnology (VIR)
Vir Biotechnology (VIR) Receives a Buy From TD Cowen
Vir Biotechnology Lowers FY24 Operating Expense Guidance >VIR
Vir Biotechnology Analyst Ratings
Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $19
Vir Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Buy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program Prospects
Buy Rating Affirmed for Vir Biotechnology on Promising HDV Program and Anticipated Trial Results
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Vir Biotechnology (VIR) and Alvotech (ALVO)
Analysts' Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)